Pantziarka Pan, Verbaanderd Ciska, Sukhatme Vidula, Rica Capistrano I, Crispino Sergio, Gyawali Bishal, Rooman Ilse, Van Nuffel An Mt, Meheus Lydie, Sukhatme Vikas P, Bouche Gauthier
The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
The George Pantziarka TP53 Trust, London, UK.
Ecancermedicalscience. 2018 Dec 6;12:886. doi: 10.3332/ecancer.2018.886. eCollection 2018.
Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project.org/db/).
药物重新利用是一种药物开发策略，旨在将现有药物用于新的适应症。在肿瘤学领域，将非癌症药物用作可能的癌症治疗方法的研究活动日益增多。肿瘤学中的药物重新利用（ReDO）项目采用了基于文献的方法来识别已获许可的非癌症药物，这些药物有已发表的抗癌活性证据。来自268种药物的数据已被纳入ReDO项目开发的数据库（ReDO_DB）。概述了总结结果，并描述了对临床试验活动的评估。该数据库已作为在线开放获取资源提供（http://www.redo-project.org/db/）。
